Page 20 of 39 · 913 questions tagged clinical-trials.
Details up front: 2 mg · dulaglutide. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
This came up because two published schedules for the same agent differ. I have read the primary source rather than the summary, which has left me with more questions.…
The particulars: REDEFINE-1 · early satiety. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
The specifics, since they change the answer: tirzepatide · 37 °C. Somebody stated this to me confidently and I would like to check it before repeating it. I would…
Details up front: cagrilintide · room temperature. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…
Details up front: mazdutide · FLOW. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how confident…
The particulars: vomiting · survodutide · STEP 3. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…
Details up front: SURMOUNT-4 · 40 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
What I have: SURMOUNT-5 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
What I have: ATTAIN-1 · dulaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…
Conditions: STEP 2 · oral semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result,…
I have three data points across nine months, which I hope is enough to see a trend. This should be a straightforward calculation and I keep getting two different…
The specifics, since they change the answer: PIONEER-1 · ecnoglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret…
Concretely: STEP 4 · liraglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…
Conditions: PIONEER-1 · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and monographs…
Stated plainly: STEP 3 · mazdutide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…
What I am working with: STEP 5 · cagrilintide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Details up front: SURMOUNT-5 · orforglipron. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want to know whether this is a real physical effect or…
Conditions: SURMOUNT-1 · injection-site erythema · 20 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading…
What I have: a GLP-1 receptor agonist · SELECT. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know…
The particulars: FLOW · 20 mg. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
The specifics, since they change the answer: SURMOUNT-5 · headache · 2 mg. I have the document in front of me and I can read the numbers. What I cannot do is…
I have read the prescribing information and it addresses the adjacent case but not this one. I can parse the result. I am less sure what it licenses me to conclude. I…